1. Home
  2. NUVB vs TECX Comparison

NUVB vs TECX Comparison

Compare NUVB & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NUVB
  • TECX
  • Stock Information
  • Founded
  • NUVB 2018
  • TECX 2019
  • Country
  • NUVB United States
  • TECX United States
  • Employees
  • NUVB N/A
  • TECX N/A
  • Industry
  • NUVB Biotechnology: Pharmaceutical Preparations
  • TECX
  • Sector
  • NUVB Health Care
  • TECX
  • Exchange
  • NUVB Nasdaq
  • TECX Nasdaq
  • Market Cap
  • NUVB 1.1B
  • TECX 387.1M
  • IPO Year
  • NUVB N/A
  • TECX 2018
  • Fundamental
  • Price
  • NUVB $3.28
  • TECX $15.06
  • Analyst Decision
  • NUVB Strong Buy
  • TECX Buy
  • Analyst Count
  • NUVB 6
  • TECX 6
  • Target Price
  • NUVB $8.17
  • TECX $79.17
  • AVG Volume (30 Days)
  • NUVB 6.7M
  • TECX 502.6K
  • Earning Date
  • NUVB 11-05-2025
  • TECX 11-06-2025
  • Dividend Yield
  • NUVB N/A
  • TECX N/A
  • EPS Growth
  • NUVB N/A
  • TECX N/A
  • EPS
  • NUVB N/A
  • TECX N/A
  • Revenue
  • NUVB $14,355,000.00
  • TECX N/A
  • Revenue This Year
  • NUVB $332.80
  • TECX N/A
  • Revenue Next Year
  • NUVB $360.12
  • TECX N/A
  • P/E Ratio
  • NUVB N/A
  • TECX N/A
  • Revenue Growth
  • NUVB 900.35
  • TECX N/A
  • 52 Week Low
  • NUVB $1.54
  • TECX $13.70
  • 52 Week High
  • NUVB $4.09
  • TECX $61.07
  • Technical
  • Relative Strength Index (RSI)
  • NUVB 58.18
  • TECX 31.98
  • Support Level
  • NUVB $3.20
  • TECX $15.92
  • Resistance Level
  • NUVB $3.41
  • TECX $18.61
  • Average True Range (ATR)
  • NUVB 0.27
  • TECX 1.60
  • MACD
  • NUVB -0.03
  • TECX -0.46
  • Stochastic Oscillator
  • NUVB 33.55
  • TECX 0.49

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

About TECX Tectonic Therapeutic Inc. Common Stock

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

Share on Social Networks: